Abstract:Background A significant challenge to overcome in pancreatic ductal adenocarcinoma (PDAC) is the profound systemic immunosuppression that renders this disease non-responsive to immunotherapy. Our supporting data provide evidence that CD200, a regulator of myeloid cell activity, is expressed in the PDAC microenvironment. Additionally, myeloid-derived suppressor cells (MDSC) isolated from patients with PDAC express elevated levels of the CD200 receptor (CD200R). Thus, we hypothesize that CD200 expression in the PDAC microenvironment limits responses to immunotherapy by promoting expansion and activity of MDSC. Methods Immunofluorescent staining was used to determine expression of CD200 in murine and human PDAC tissue. Flow cytometry was utilized to test for CD200R expression by immune populations in patient blood samples. In vivo antibody blocking of CD200 was conducted in subcutaneous MT-5 tumor-bearing mice and in a genetically engineered PDAC model (KPC-Brca2 mice). Peripheral blood mononuclear cells (PBMC) from patients with PDAC were analyzed by single-cell RNA sequencing. MDSC expansion assays were completed using healthy donor PBMC stimulated with IL-6/GM-CSF in the presence of recombinant CD200 protein. Results We found expression of CD200 by human pancreatic cell lines (BxPC3, MiaPaca2, and PANC-1) as well as on primary epithelial pancreatic tumor cells and smooth muscle actin+ stromal cells. CD200R expression was found to be elevated on CD11b+CD33+HLA-DR lo/− MDSC immune populations from patients with PDAC (p=0.0106). Higher expression levels of CD200R were observed in CD15+ MDSC compared with CD14+ MDSC (p<0.001). In vivo studies demonstrated that CD200 antibody blockade limited tumor progression in MT-5 subcutaneous tumor-bearing and in KPC-Brca2 mice (p<0.05). The percentage of intratumoral MDSC was significantly reduced in anti-CD200 treated mice compared with controls. Additionally, in vivo blockade of CD200 can also significantly enhance the efficacy of PD-1 checkpoint antibodies compared with single antibody therapies (p<0.05). Single-cell RNA sequencing of PBMC from patients revealed that CD200R+ MDSC expressed genes involved in cytokine signaling and MDSC expansion. Further, in vitro cytokine-driven expansion and the suppressive activity of human MDSC was enhanced when cocultured with recombinant CD200 protein. Conclusions These results indicate that CD200 expression in the PDAC microenvironment may regulate MDSC expansion and that targeting CD200 may enhance activity of checkpoint immunotherapy.

CD300ld on neutrophils is required for tumour-driven immune suppression

Targeting polymorphonuclear myeloid‐derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy

Targeting CD300ld to normalize the tumor microenvironment: an emerging insight in cancer immunotherapy

CD300ld on Neutrophils Drives Immune Suppression and Tumor Growth.

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

Rational targeting of immunosuppressive neutrophils in cancer

CD177(+) Neutrophils Suppress Epithelial Cell Tumourigenesis in Colitis-Associated Cancer and Predict Good Prognosis in Colorectal Cancer

Pan‐cancer analysis identifies CD300 molecules as potential immune regulators and promising therapeutic targets in acute myeloid leukemia

The Blockage of Notch Signalling Promoted the Generation of Polymorphonuclear Myeloid-Derived Suppressor Cells with Lower Immunosuppression.

CD200 promotes immunosuppression in the pancreatic tumor microenvironment

A CXCR4 partial agonist improves immunotherapy by targeting polymorphonuclear myeloid-derived suppressor cells and cancer-driven granulopoiesis

Role of CXCR3 Signaling in Response to Anti-Pd-1 Therapy.

CD300e as a Driver of Immunosuppressive Tumor Microenvironment in Colorectal Cancer

CD200R Signaling Contributes to Unfavorable Tumor Microenvironment Through Regulating Production of Chemokines by Tumor-Associated Myeloid Cells

Myeloid‐derived suppressor cells from tumour‐bearing mice induce the population expansion of CD19hiFcγRIIbhi regulatory B cells via PD‐L1

CD45+CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8+ T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer

The Association Between Monocytic Myeloid-Derived Suppressor Cells Levels and the Anti-Tumor Efficacy of Anti-Pd-1 Therapy in NSCLC Patients

CD155/CD96 promotes immunosuppression in lung adenocarcinoma (LUAD)

Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c+ Conventional Dendritic Cell Subsets Mediated by CD103 and CD205

The MDM2 Ligand Nutlin-3 Differentially Alters Expression of the Immune Blockade Receptors PD-L1 and CD276